Comparative clinical effects and cost-effectiveness of maximum androgen blockade, docetaxel with androgen deprivation therapy and ADT alone for the treatment of mHSPC in China.
Conclusion: Doc-ADT is likely the optimal option from the perspective of both clinical outcomes and economic considerations.
PMID: 31476895 [PubMed - in process]
Source: Journal of Comparative Effectiveness Research - Category: General Medicine Tags: J Comp Eff Res Source Type: research
More News: Cancer | Cancer & Oncology | China Health | Docetaxel | General Medicine | Hormones | Prostate Cancer | Taxotere